

# UPTAKE, LOCALIZATION, AND NONCARBOXYLASE ROLES OF BIOTIN\*

Janos Zempleni

*Department of Nutrition and Health Sciences and Departments of Biochemistry and Animal Science, University of Nebraska at Lincoln, Nebraska 68583-0806; email: Jzempleni2@unl.edu*

**Key Words** biotin, cell signaling, gene expression, histones, transport

■ **Abstract** Evidence is emerging that biotin participates in processes other than classical carboxylation reactions. Specifically, novel roles for biotin in cell signaling, gene expression, and chromatin structure have been identified in recent years. Human cells accumulate biotin by using both the sodium-dependent multivitamin transporter and monocarboxylate transporter 1. These transporters and other biotin-binding proteins partition biotin to compartments involved in biotin signaling: cytoplasm, mitochondria, and nuclei. The activity of cell signals such as biotinyl-AMP, Sp1 and Sp3, nuclear factor (NF)- $\kappa$ B, and receptor tyrosine kinases depends on biotin supply. Consistent with a role for biotin and its catabolites in modulating these cell signals, greater than 2000 biotin-dependent genes have been identified in various human tissues. Many biotin-dependent gene products play roles in signal transduction and localize to the cell nucleus, consistent with a role for biotin in cell signaling. Posttranscriptional events related to ribosomal activity and protein folding may further contribute to effects of biotin on gene expression. Finally, research has shown that biotinidase and holocarboxylase synthetase mediate covalent binding of biotin to histones (DNA-binding proteins), affecting chromatin structure; at least seven biotinylation sites have been identified in human histones. Biotinylation of histones appears to play a role in cell proliferation, gene silencing, and the cellular response to DNA repair. Roles for biotin in cell signaling and chromatin structure are consistent with the notion that biotin has a unique significance in cell biology.

## CONTENTS

|  |     |
|--|-----|
| INTRODUCTION .....                                     | 176 |
| CELLULAR UPTAKE AND DISTRIBUTION .....                 | 176 |
| Biotin Transporters in the Plasma Membrane .....       | 177 |
| Biotin Homeostasis in the Central Nervous System ..... | 178 |

\***ABBREVIATIONS:** CNS, central nervous system; ER, endoplasmic reticulum; HCS, holocarboxylase synthetase;  $K_m$ , Michaelis-Menten constant; MCT, monocarboxylate transporter; PBMC, peripheral blood mononuclear cells; SMVT, sodium-dependent multivitamin transporter; UPR, unfolded protein response.

|   |     |
|---|-----|
| Biotin Uptake into Cellular Organelles .....                  | 178 |
| CELL SIGNALING .....  | 179 |
| Gene Expression .....   | 179 |
| Biotinyl-AMP .....  | 180 |
| Nuclear Factor- $\kappa$ B .....                              | 181 |
| Sp1 and Sp3 .....   | 182 |
| Receptor Tyrosine Kinase Signaling .....                      | 183 |
| Biotin Catabolites .....                                      | 184 |
| Posttranscriptional Events .....                              | 185 |
| HISTONES .....  | 185 |
| Chromatin Structure .....                                     | 185 |
| Enzymatic Biotinylation and Debiotinylation of Histones ..... | 186 |
| Identification of Biotinylation Sites .....                   | 187 |
| Biological Functions of Histone Biotinylation .....           | 188 |
| Biotin Supply .....   | 188 |
| CONCLUSIONS AND OUTLOOK .....                                 | 189 |

INTRODUCTION

Soon after the discovery of biotin by Boas (12) and Kogl & Tonnis (75), biochemical functions of the vitamin were unveiled. It was demonstrated that biotin serves as a covalently bound coenzyme for the following carboxylases in eukaryotes: acetyl-CoA carboxylase, pyruvate carboxylase, propionyl-CoA carboxylase, and 3-methylcrotonyl-CoA carboxylase (74, 144). For acetyl-CoA carboxylase, a cytosolic (denoted acetyl-CoA carboxylase  $\alpha$ ) and a mitochondrial (denoted acetyl-CoA carboxylase  $\beta$ ) form have been identified; the distinct functions of these isoforms in fatty acid metabolism have been reviewed (73). Acetyl-CoA carboxylase  $\beta$  may also play a role in biotin storage (120). Additional biotin-dependent carboxylases have been identified in prokaryotes (7, 49, 74, 144). Binding of biotin to carboxylases in eukaryotic cells is mediated by holocarboxylase synthetase (HCS); biotinyl-AMP occurs as an intermediate (44). Recycling of covalently bound biotin from breakdown products of carboxylases is mediated by biotinidase (142).

In the late 1960s and early 1970s, evidence began to emerge that biotin affects gene expression in mammals (45, 46). These pioneering studies can be considered the starting point for many of the exciting developments that the field of biotin research has witnessed in the recent past. Beginning with an improved understanding of cellular biotin uptake and localization, it became evident very quickly that biotin plays essential roles in cell signaling and chromatin structure. These recent advances in cellular uptake and localization, and the noncarboxylase roles of biotin, are reviewed in this chapter.

CELLULAR UPTAKE AND DISTRIBUTION

Mechanisms of biotin uptake into mammalian cells have been reviewed in detail in recent volumes in the *Annual Reviews* series (90, 116). The reader is referred to these reviews for a detailed account of biotin transporters. Here we provide a

brief update on biotin transporters located in the plasma membrane. Factors that determine the intracellular distribution of biotin are also discussed as they relate to newly discovered noncarboxylase roles of the vitamin.

## Biotin Transporters in the Plasma Membrane

Early investigations of biotin transport in mammals provided evidence for the existence of a biotin carrier in plasma membranes (17, 18, 35). These studies suggested that uptake of biotin is a sodium-dependent process that requires metabolic energy. The Michaelis-Menten constant ( $K_m$ ) of the biotin transporter in mouse fibroblasts 3T3-L1 and mouse jejunum is 22 and 3.7  $\mu\text{mol/L}$ , respectively (35, 117). At high extracellular concentrations of biotin ( $[\text{biotin}] \gg K_m$ ), passive diffusion of biotin into cells gains importance and exceeds carrier-mediated influx (18, 35). Both carrier-mediated uptake and passive diffusion account for the very efficient uptake of biotin observed in mammals. Oral doses of biotin that exceed the normal dietary intake by about 600 times are absorbed completely (150).

The biotin transporter in mammalian cells has broad substrate specificity and carries biotin, pantothenic acid, and lipoic acid (103) with similar affinity (105). Consequently, this transporter was named the sodium-dependent multivitamin transporter (SMVT) (105). The SMVT has been detected in numerous cell lines from various species (103–105, 116). Four variants of SMVT transcripts have been identified in rats (28). The role of SMVT in biotin transport was confirmed by cloning a cDNA coding for rat SMVT, and expressing functional transporter in human-derived HeLa cells (105). Likewise, rabbit intestinal SMVT was functionally expressed in human retinal pigment epithelium (104).

The intestinal biotin uptake is regulated by protein kinase C and  $\text{Ca}^{2+}$ /calmodulin-mediated pathways (115). Activation of protein kinase C inhibits biotin uptake, whereas inhibition of protein kinase C stimulates biotin uptake by Caco-2 cells. This effect of protein kinase C is mediated by alterations in the activity or abundance of biotin transporters, as opposed to alterations in transporter affinity for substrate. SMVT contains two putative protein kinase C phosphorylation sites (28, 104, 115), but it is unknown whether these sites are involved in the regulation of biotin uptake by protein kinase C.

The 5'-regulatory regions of *SMVT* genes in rats and humans have been cloned and characterized (29, 48). The rat and human *SMVT* genes contain three and two distinct promoters, respectively. Both promoter sequences in the human gene are TATA-less, CAAT-less, contain highly GC-rich sites, and have multiple putative regulatory *cis*-elements, e.g., AP-1, AP-2, C/EBP, SP1, NF1, and GATA (48). The minimal region required for basal activity of the human SMVT promoter is encoded by a sequence between –5846 and –5313 for promoter 1 and between –4417 and –4244 for promoter 2 relative to the translation initiation codon. The three promoters in the rat SMVT gene contain *cis*-elements similar to the elements observed in the human promoters, but the rat 5'-regulatory region also contains two TATA-like elements (29).

Notwithstanding the important role of SMVT in biotin uptake, the following lines of evidence suggest that transporters other than SMVT also mediate biotin

uptake in some human tissues. First, the  $K_m$  for biotin uptake into human peripheral blood mononuclear cells (PBMC) is about 1000 times smaller than the  $K_m$  for biotin transport by SMVT (57, 149, 152). Second, both lipoic acid and pantothenic acid are substrates for SMVT but do not compete with biotin for uptake into PBMC (149, 152). Third, an inborn error in biotin transport does not affect transport of pantothenic acid in PBMC (87). Fourth, human lymphoid (Jurkat) cells respond to biotin deficiency with increased rates of biotin uptake without increasing the expression of SMVT (85).

Eventually evidence was provided that biotin uptake into human lymphoid cells is mediated by monocarboxylate transporter 1 (MCT1) in addition to SMVT (42). Notwithstanding the ubiquitous expression of MCT1 in human tissues (61), it remains to be demonstrated whether MCT1 plays a role in biotin uptake in tissues other than lymphoid cells (42). MCT1 belongs to the family of monocarboxylate transporters. Nine MCT-related sequences have so far been identified in mammals, each having a distinct tissue distribution (61). It is unknown if MCTs other than MCT1 play a role in biotin uptake.

## Biotin Homeostasis in the Central Nervous System

Disturbances in biotin homeostasis in the central nervous system (CNS) cause encephalopathies (41, 95). Factors leading to biotin imbalances in CNS include deficiencies of biotinidase, HCS (41), and perhaps biotin transporters (87, 95). Afflicted patients typically respond to the administration of large doses of biotin with maintaining normal neurological function (41, 95).

Moderate dietary biotin deficiency is typically not associated with neurological symptoms. This is consistent with the hypothesis that under conditions of moderate biotin deficiency the CNS maintains normal concentrations of biotin at the expense of other tissues. Indeed, research has shown that biotin deficiency causes a >90% decrease of biotinylated carboxylases in rat liver, whereas brain carboxylases remain unchanged (96). Apparently, biotin deficiency decreases expression of SMVT in rat liver while maintaining normal expression of SMVT in brain (96).

## Biotin Uptake into Cellular Organelles

Biotin is distributed unequally across cellular compartments (100). If [ $^{14}\text{C}$ ]biotin is administered intravenously to rats, the vast majority of biotin in liver localizes to mitochondria and cytoplasm, whereas only a small fraction localizes to microsomes (100). The relative enrichment of biotin in mitochondria and cytoplasm is consistent with the role of biotin as a coenzyme for carboxylases in these compartments. A quantitatively small but qualitatively important fraction of biotin localizes to the cell nucleus, i.e., about 0.7% of total biotin in human PBMC can be recovered from the nuclear fraction (128). The relative abundance of nuclear biotin increases to about 1% of total biotin in response to proliferation, consistent with a role for nuclear biotin-binding proteins (histones) in cell proliferation as described in the "Biological Functions of Histone Biotinylation" section.

What are the mechanisms driving the cellular partitioning of biotin? Theoretically, both transport by MCT1 (42) and binding to carboxylases (73, 74, 144) might mediate the sequestration of biotin in mitochondria. MCT1 is known to transport biotin (42) and has been detected in mitochondrial membranes (22, 61). After entry into mitochondria, biotin is trapped by covalent binding to acetyl-CoA carboxylase  $\beta$ , pyruvate carboxylase, propionyl-CoA carboxylase, and 3-methylcrotonyl-CoA carboxylase (74, 144). Studies of biotin turnover in human PBMC suggested that the half-life of biotin during the slow phase of elimination (half-life =  $21.9 \pm 13.6$  h) coincides with the breakdown of biotinylated carboxylases (151). Similar findings were made for biotin and holo-pyruvate carboxylase in the mouse preadipocyte cell line 3T3-L1 (54). Depletion and repletion studies of biotin-dependent carboxylases in rat liver are consistent with a role for mitochondrial acetyl-CoA carboxylase  $\beta$  in biotin storage (120).

Binding of biotin to proteins in cytoplasm and nucleus is likely to mediate the sequestration of biotin in these compartments. In cytoplasm, acetyl-CoA carboxylase  $\alpha$  is the primary biotin-binding protein (147). In the cell nucleus, histones are the primary biotin-binding proteins (128).

## CELL SIGNALING

### Gene Expression

Pioneering studies by Dakshinamurti and coworkers (43, 45, 46) provided evidence that biotin affects gene expression in addition to its classical role as a coenzyme for carboxylases. Specifically, these studies revealed that biotin deficiency in rats causes a 40% to 45% reduction of liver glucokinase activity, and that normal enzyme activity can be restored by biotin administration (45). Administration of biotin increases the amount of mRNA coding for glucokinase in rat liver (30, 126) and in cultured beta cells (14). These observations broke the ground for current investigations at the interface of biotin, cell signaling, gene expression, and human health.

DNA microarray studies have substantially expanded the number of genes known to be affected by biotin. Most of these studies were conducted using human PBMC and hepatocarcinoma (HepG2) cells. As of today, researchers have identified greater than 2000 human genes that depend on biotin for expression (109, 139, 140). Apparently, biotin-dependent genes are not randomly distributed in the human genome but are arranged in clusters. For example, supplementation of healthy adults with  $8.8 \mu\text{mol/d}$  of biotin for 21 days was associated with increased and decreased expression of 139 and 131 genes, respectively, in PBMC compared with before biotin supplementation (140). The following clusters of biotin-responsive genes were identified in this study. First, if genes were clustered by biological function, biotin-dependent genes were overrepresented among genes associated with cell signaling. For example, at least 28% of biotin-responsive genes play roles in signal transduction, and 16% of products from biotin-responsive genes localize to the cell nucleus. Second, if genes were clustered by chromosomal location,

54% of biotin-responsive genes clustered on chromosomes 1, 2, 3, 11, 12, and 19, whereas no biotin-responsive genes were found on chromosomes 10, 16, 18, 21, and heterosomes. This suggests that position effects play a role in biotin-dependent gene expression.

In another study, human HepG2 cells were cultured in media containing deficient, physiological, and pharmacological concentrations of biotin or the catabolite bisnorbiotin (109). Approximately 1800 biotin-dependent genes were identified. A large number of biotin-dependent genes could be assigned to one of the following clusters based on molecular function: DNA-binding proteins, RNA-binding proteins, genes that play roles in translational activity, nucleotide-binding proteins, and proteins with transferase activity. Gene clusters associated with DNA-binding proteins, RNA-binding proteins, and nucleotide-binding proteins are consistent with a role of biotin in cell signaling and chromatin structure as described below.

The mechanisms that mediate the occurrence of biotin-dependent gene clusters are currently unknown. Both common regulatory elements in biotin-dependent genes and biotin-dependent remodeling of chromatin appear to play a role in this process. The following cell signals and transcription factors mediate effects of biotin on gene expression: (a) biotinyl-AMP and cGMP (125); (b) nuclear factor (NF)- $\kappa$ B (112); (c) Sp1 and Sp3 (59); and (d) receptor tyrosine kinases. These signaling pathways are reviewed in the following sections; biotin-dependent remodeling of chromatin is discussed further in the "Chromatin Structure" section.

## Biotinyl-AMP

Biotinyl-AMP is an intermediate in the synthesis of biotin-dependent holocarboxylases, catalyzed by HCS (147). In mammalian cells, HCS is localized in cytosol, mitochondria, and nucleus (27, 33, 94). Solorzano-Vargas et al. (125) proposed that biotinyl-AMP plays an essential role in regulating gene expression. According to this model, biotinyl-AMP activates soluble guanylate cyclase by a yet unknown mechanism; activation of guanylate cyclase increases the synthesis of cGMP (125). cGMP stimulates protein kinase G, leading to phosphorylation and activation of proteins that enhance the transcription of genes encoding HCS and some carboxylases. Transcriptional activation of these genes is impaired by both biotin deficiency and decreased activity of HCS; the latter can be observed in an inborn error of metabolism known as multiple carboxylase deficiency (131, 142). Consistent with the model described above, addition of biotin to biotin-deficient culture medium increased the activity of guanylate cyclase in both HeLa cells and fibroblasts (122). It remains to be determined whether activation of guanylate cyclase by biotinyl-AMP also plays a role in regulating the expression of genes other than holocarboxylase synthetase and carboxylases. Circumstantial evidence has shown that activation of guanylate cyclase by biotin supplementation is associated with increased activity of RNA polymerase II in HeLa cells and fibroblasts (122). These effects were observed at a concentration of 10 nmol/L biotin (122), which can be readily achieved in healthy adults by biotin supplementation (148).

Biotinyl-AMP-dependent cell signaling is also known from microorganisms. In *Escherichia coli* and other enteric bacteria, biotinyl-AMP [complexed with BirA (biotin-protein ligase), the microbial homolog of HCS] affects gene expression. The biotinyl-AMP/BirA complex binds to promoter regions in the biotin operon, a cluster of genes mediating biotin biosynthesis; binding of biotinyl-AMP/BirA represses the transcription of these genes (40). This feedback loop prevents excessive biosynthesis of biotin.

## Nuclear Factor- $\kappa$ B

The transcription factor NF- $\kappa$ B regulates processes such as prevention of cell death, immune function, and embryonic development (81). Five members of the mammalian NF- $\kappa$ B/Rel family of transcription factors have been identified: c-Rel, NF- $\kappa$ B1 (p50/p105), NF- $\kappa$ B2 (p52/p100), RelA (p65), and RelB (4). Transcriptional activation of genes by NF- $\kappa$ B proceeds along the following mechanistic sequence. In unstimulated cells, heterodimers and homodimers of proteins from the NF- $\kappa$ B family reside in the cytoplasm (4). These inactive dimers are associated with the following monomers of inhibitors of NF- $\kappa$ B: I $\kappa$ B $\alpha$  or I $\kappa$ B $\beta$  (4). Binding to I $\kappa$ B retains NF- $\kappa$ B in the cytoplasm by masking the nuclear localization sequences (4). Stimulation of I $\kappa$ B kinases by bacteria, cytokines, mitogens, oxidative stress, growth factors, and hormones triggers phosphorylation of I $\kappa$ Bs, which are then degraded in proteasome-dependent pathways (81). The liberated NF- $\kappa$ B dimers translocate to the cell nucleus, where they bind to response elements in regulatory regions of genes, triggering gene expression.

Research has shown that biotin affects cell signaling by NF- $\kappa$ B (112). In these studies, human-derived lymphoma (Jurkat) cells were cultured in biotin-deficient and biotin-supplemented media for five weeks; cells were stimulated with phytohemagglutinin and phorbol-12-myristate-13-acetate to induce nuclear translocation of NF- $\kappa$ B. The following observations are consistent with the hypothesis that biotin supply affects NF- $\kappa$ B signaling: (a) the nuclear abundance of p50 and p65 is greater in biotin-deficient cells compared with biotin-supplemented cells; (b) the DNA-binding activity of NF- $\kappa$ B is greater in biotin-deficient cells compared with biotin-supplemented cells; (c) the transcriptional activity of NF- $\kappa$ B-dependent reporter genes is greater in biotin-deficient cells compared with biotin-supplemented cells; and (d) the activity of I $\kappa$ B $\alpha$  kinases is greater in biotin-deficient cells compared with biotin-supplemented cells, consistent with increased rates of I $\kappa$ B $\alpha$  degradation and nuclear translocation of NF- $\kappa$ B.

Many cancer cells activate NF- $\kappa$ B in response to treatment with antineoplastic drugs (13, 47, 138), mediating expression of antiapoptotic genes such as *Bfl-1/A1* (6, 52, 66, 81). The products of these genes enhance survival of cancer cells (70, 137, 138), causing resistance to chemotherapy. Research has shown that biotin deficiency enhances the nuclear translocation of NF- $\kappa$ B in Jurkat cells treated with antineoplastic agents such as taxol, doxorubicin, and vinblastine (60). This is associated with increased expression of *Bfl-1/A1* and a decreased rate of death in cells treated with doxorubicin and vinblastine. It is uncertain whether

biotin status of cancer patients affects the resistance to chemotherapy *in vivo*. Notwithstanding this uncertainty, effects of biotin on NF- $\kappa$ B activity and cell survival are of potential relevance for health care professionals, given the high prevalence of nutrient deficiencies in cancer patients and during chemotherapy (71, 123, 124).

## Sp1 and Sp3

Sp1 and Sp3 belong to the Sp/Krüppel-like factor (KLF) family of transcription factors, which contains at least 20 distinct proteins in mammals (11). Some members of this family are widespread or ubiquitously expressed, whereas other members are highly restricted in their tissue distribution (11). Sp/KLF transcription factors have overlapping DNA-binding specificities and bind to GC-rich sequences (e.g., GC boxes, CACCC boxes) located in regulatory regions of numerous genes; these sequences are collectively referred to as Sp1 sites. Competition among family members for binding to regulatory sequences in DNA plays an important role in the regulation of gene expression (11). Sp/KLF transcription factors differ in their transcriptional activity, with some being activating and some being repressive, establishing a very complex network of regulation. For example, Sp3 may repress Sp1-dependent activation of genes encoding dihydrofolate reductase and  $\alpha 1(\text{II})$  procollagen by competing with Sp1 for binding to Sp1 sites (10, 55).

The nuclear abundance of Sp1 and Sp3 depends on biotin status in Jurkat cells; the DNA-binding activity of Sp1 and Sp3 is up to 149% greater in biotin-supplemented cells compared with biotin-deficient cells (59). The increased DNA-binding activity in biotin-supplemented cells is mediated by increased expression of genes coding for Sp1 and Sp3. In contrast, posttranslational phosphorylation of Sp1 and Sp3 [a modification known to affect DNA-binding activity (2, 80, 93, 114)] does not depend on biotin (59). Preliminary evidence suggests that Sp1 and Sp3 might be directly modified by covalent binding of biotin (J. Zempléni, unpublished observation). The increased nuclear abundance of Sp1 and Sp3 in biotin-supplemented cells is associated with increased transcriptional activity of Sp1/Sp3-dependent reporter-gene constructs compared with biotin-deficient controls (59).

Effects of biotin on the nuclear abundance of Sp1 and Sp3 are physiologically important. First, the increased nuclear abundance of Sp1 and Sp3 in biotin-supplemented lymphoid cells is associated with increased expression of the *cytochrome P450 1B1* gene (108). The 5'-flanking region of the human *cytochrome P450 1B1* gene contains 11 Sp1 sites (132, 135, 141). Cytochrome P450 1B1 hydroxylates xenobiotics and estrogens ("metabolic activation"), creating electrophilic mutagens that may cause single-stranded breaks in DNA and 8-hydroxylation of guanine bases in DNA (64, 82). Indeed, biotin supplementation is associated with increased frequency of DNA strand breaks in lymphoid cells (108).

Second, biotin supplementation is associated with decreased transcription of the *sarco/endoplasmic reticulum ATPase3* (*SERCA3*) gene (58), the expression of



which is controlled by 25 Sp1 sites in its 5'-flanking region (50). Given that Sp3 may act as transcriptional repressor, it has been proposed that effects of biotin on SERCA3 expression are mediated by the increased nuclear abundance of Sp3 in biotin-supplemented cells (58). Decreased expression of SERCA3 reduces the sequestration of calcium in the endoplasmic reticulum (ER) (83). This impairs activities of calcium-dependent proteins such as calnexin (8, 63), BiP (84), and protein disulfide isomerase (84), which play essential roles in the folding of secretory proteins. Accumulation of unfolded proteins in the ER triggers a process named the unfolded protein response (UPR) (121). Hallmarks of UPR include a low global translational activity, a specific increase in the expression of chaperones and other stress-related proteins, a decreased rate of cell proliferation, and an increase in apoptotic activity (20, 25, 97, 106, 121, 146). The following lines of evidence suggest that low expression of SERCA3 in biotin-supplemented cells impairs protein folding in the ER, triggering UPR (58): (a) sequestration of calcium in the ER decreased by 30% in response to biotin supplementation; (b) secretion of interleukin-2 into the extracellular space decreased by 75% in response to biotin supplementation; and (c) the abundance of stress-related proteins such as UBE1, GADD153, XBP1, and phosphorylated eIF2 $\alpha$  increased in response to biotin supplementation.

## Receptor Tyrosine Kinase Signaling

Receptor tyrosine kinases span the membranes of mammalian cells (65). Various ligands have affinity for the ligand-binding site located in the extracellular domain of receptor tyrosine kinases; ligands include platelet-derived growth factor, insulin, thrombin, and various other compounds. Binding of ligands causes dimerization of receptors and activation of the tyrosine kinase domain located in the cytoplasmic region; this is associated with autophosphorylation of the C-terminus of the receptor. Phosphorylated receptor has affinity for GRB2 (and perhaps its homolog SAM68) and SOS. Binding of the G protein SOS to the phosphorylated receptor tyrosine kinase triggers a substitution of GTP for GDP in the serine/threonine kinase Ras, leading to its catalytic activation. Phosphorylated Ras mediates phosphorylation and, hence, activation of the serine/threonine kinase RAF1. RAF1 phosphorylates MAP kinase kinases (MAPKK or MEK). Phosphorylated MEK catalyze phosphorylation and, hence, activation of mitogen-activated protein kinases (MAPK) such as ERK1 and ERK2. Phosphorylated ERK mediate phosphorylation of the transcription factors Fos and Jun, which bind to AP1 sites in regulatory regions of genes, causing transcriptional activation.

Research has shown that biotin deficiency activates signaling by receptor tyrosine kinases. In these studies, human hepatocarcinoma (HepG2) cells were cultured in media containing deficient, physiological, or pharmacological concentrations of biotin for 10 days (107). Proteins in cell extracts were quantified using high-throughput immunoblots. Biotin deficiency was associated with increased abundance of GRB2, SAM68, and RAF1; the abundance of the Ras-interacting protein

AF6 decreased to nondetectable levels in response to biotin deficiency, enhancing the activity of Ras. Activation of receptor tyrosine kinase pathways was associated with nuclear translocation of AP1-binding proteins Jun and Fos, and transcriptional activation of AP1-dependent reporter genes in biotin-deficient HepG2 cells. The physiological significance of this finding is uncertain. AP1 sites render genes responsive to stimulation with phorbol esters (77); the 5'-flanking region of the human *SMVT* gene also contains AP1 sites (48). Theoretically, activation of receptor tyrosine kinase signaling in biotin-deficient cells may contribute to increasing *SMVT*-mediated biotin uptake.

## Biotin Catabolites

McCormick and coworkers have described the two major pathways of biotin catabolism in a series of seminal papers (89). In the first pathway, biotin is catabolized by  $\beta$ -oxidation of the valeric acid side chain, generating compounds such as bisnorbiotin and tetranorbiotin. In the second pathway, the sulfur in the thiophane portion of the biotin molecule is oxidized, generating compounds such as biotin-*d*, *l*-sulfoxides and biotin sulfone. Combinations of both  $\beta$ -oxidation and sulfur oxidation also occur to generate compounds such as tetranorbiotin-*l*-sulfoxide. Biotin catabolites are quantitatively important in mammalian body fluids and cells; the total concentration of biotin catabolites approximately equals the concentration of intact biotin (91, 92).

Evidence emerged that biotin catabolites may play roles in cell signaling. In Jurkat cells, biotin deficiency is associated with decreased expression of the genes encoding interleukin-2 and interleukin-2 receptor gamma (110). Supplementation of biotin-deficient culture medium with the synthetic biotin derivatives diaminobiotin and desthiobiotin restored expression of interleukin-2 and interleukin-2 receptor gamma to control levels (110). Supplementation of culture media with diaminobiotin and desthiobiotin did not affect the abundance of holocarboxylases and activities of propionyl-CoA carboxylase. Hence, effects of biotin analogs on gene expression are not mediated by carboxylase-dependent pathways. Modulation of gene expression by biotin analogs extends to naturally occurring biotin catabolites. For example, supplementation of culture medium with bisnorbiotin altered the expression of 618 genes in HepG2 cells (109).

The mechanisms by which biotin catabolites affect gene expression are uncertain. Note that HCS cannot convert biotin analogs such as desthiobiotin to AMP esters (134); in addition, biotin analogs such as biocytin (biotin- $\epsilon$ -lysine), desthiobiotin, diaminobiotin, and iminobiotin do not inhibit the enzymatic conversion of biotin to biotinyl-AMP, suggesting that these analogs do not compete with biotin for binding to HCS (134). Thus, effects of biotin catabolites on gene expression cannot be explained by the biotinyl-AMP model. Future studies are likely to reveal the mechanism by which biotin catabolites modify gene expression, including the possibility that catabolites may have a biotin-sparing effect in human cells. Notwithstanding the uncertainties described above, effects of biotin catabolites on gene expression are of important consideration for nutritionists. Given that biotin

catabolites account for at least 50% of total biotinyl compounds in mammalian tissues (and, hence, foodstuffs) (91), previous studies may have underestimated the true food content and dietary intake of bioactive biotinyl compounds.

## Posttranscriptional Events

Effects of biotin on gene expression and cell signaling are not limited to the transcriptional level but also include posttranscriptional events. The earliest studies pointing to a role for biotin in posttranscriptional events date back to the late 1980s (38). These studies provided evidence that the expression of the asialoglycoprotein receptor is reduced in biotin-deficient HepG2 cells, whereas total cellular protein content and mRNA coding for the asialoglycoprotein receptor are comparable to those of control cells; addition of biotin or biocytin to culture media restored receptor expression (38). Analogous studies of propionyl-CoA carboxylase in rat hepatocytes suggested that biotin might also affect the expression of this carboxylase at a posttranscriptional step (111). The mechanisms leading to these effects of biotin are largely unknown. Theoretically, the formation of translation initiation complexes may depend on biotin. Consistent with this notion, the expression of ribosomal subunits LP2, L27a, L38, S11, and S19 and translation initiation factor eIF5A increases in response to biotin deficiency in HepG2 cells (109). In contrast, expression of the ribosomal subunits L37a, S5, and S21 increases in response to biotin supplementation.

## HISTONES

### Chromatin Structure

Chromatin in the mammalian cell nucleus is composed primarily of DNA and DNA-binding proteins, i.e., histones and nonhistone proteins. Histones play a predominant role in the folding of DNA into chromatin (143). Five major classes of histones have been identified in mammals: H1, H2A, H2B, H3, and H4. Histones are small proteins (11 to 22 kDa) consisting of a globular domain and a more flexible amino terminus (histone "tail"). Lysine and arginine residues combined account for >20% of all amino acid residues in histones, leading to a positive net charge of these proteins at physiological pH (143).

DNA and histones form repetitive nucleoprotein units, the nucleosomes (143). Each nucleosome ("nucleosomal core particle") consists of 146 base pairs of DNA wrapped around an octamer of core histones (one H3-H3-H4-H4 tetramer and two H2A-H2B dimers). The binding of DNA to histones is of electrostatic nature, and is mediated by the association of negatively charged phosphate groups of DNA with positively charged  $\epsilon$ -amino groups (lysine moieties) and guanidino groups (arginine moieties) of histones. The DNA located between nucleosomal core particles is associated with histone H1.

The amino terminal tail of histones protrudes from the nucleosomal surface; covalent modifications of this tail affect the structure of chromatin and form the basis

for gene regulation (21, 56, 69, 88, 101, 133), mitotic and meiotic chromosome condensation (34), and DNA repair (1, 9, 16, 51, 72, 145). Histone tails are modified by covalent acetylation (3, 62, 79), methylation (143), phosphorylation (143), ubiquitination (143), poly (ADP-ribosylation) (15, 16, 26), and biotinylation (see below) of  $\epsilon$ -amino groups (lysine), guanidino groups (arginine), carboxyl groups (glutamate), and hydroxyl groups (serine). Multiple signaling pathways converge on histones to mediate covalent modifications of specific amino acid residues (31, 78). Site-specific modifications of histones have distinct functions; for example, dimethylation of lysine-4 in histone H3 is associated with transcriptional activation of surrounding DNA (53, 69). Modifications of histone tails ("histone code") considerably extend the information potential of the DNA code and gene regulation (69, 129, 136). Modifications of histone tails may affect binding of chromatin-associated proteins, triggering cascades of downstream histone modifications. For example, methylation of arginine-3 in histone H4 recruits the histone acetyl transferase Esa1 to yeast chromatin, leading to acetylation of lysine-5 in histone H4 (69). Histone modifications can influence each other in synergistic or antagonistic ways, mediating gene regulation. For example, phosphorylation of serine-10 inhibits methylation of lysine-9 in histone H3, but it is coupled with acetylation of lysine-9 and lysine-14 during mitogenic stimulation in mammalian cells (69). Covalent modifications of histones can be reversed by a large variety of enzymatic processes (69).

## Enzymatic Biotinylation and Debiotinylation of Histones

Histones are modified by covalent attachment of the vitamin biotin. Hymes et al. (67, 68, 113) have proposed a reaction mechanism by which cleavage of biocytin (biotin- $\epsilon$ -lysine) by biotinidase leads to the formation of a biotinyl-thioester intermediate (cysteine-bound biotin) at or near the active site of biotinidase. In a next step, the biotinyl moiety is transferred from the thioester to the  $\epsilon$ -amino group of lysine in histones. Biocytin is generated in the breakdown of biotin-dependent carboxylases, which contain biotin linked to the  $\epsilon$ -amino group of a lysine moiety (102, 142).

Biotinidase belongs to the nitrilase superfamily of enzymes, which consists of 12 families of amidases, N-acyltransferases, and nitrilases (19). Some members of the nitrilase superfamily (vanins-1, -2, and -3) share significant sequence similarities with biotinidase (86); it is unknown whether vanins use histones as acceptor molecules in transferase reactions. Biotinidase is ubiquitous in mammalian cells and 26% of the cellular biotinidase activity is located in the nuclear fraction (102). Human biotinidase has been characterized at the gene level (36, 37). The 5'-flanking region of exon 1 contains a CCAAT element, three initiator sequences, an octamer sequence, three methylation consensus sites, two GC boxes, and one HNF-5 site, but has no TATA element (37). The 62-amino acid region that harbors the active site of biotinidase is highly conserved among various mammals and *Drosophila* (130).

Subsequent to the elucidation of the biotinidase-mediated mechanism of histone biotinylation *in vitro* (67, 68), biotinylated histones H1, H2A, H2B, H3, and H4 were detected in human PBMC *in vivo* (128). Biotinylated histones were also detected in human lymphoma cells (85), small cell lung cancer cells (119), chorio-carcinoma cells (39), and chicken erythrocytes (98). These studies also suggested that biotinidase may not be the only enzyme mediating histone biotinylation. For example, evidence showed that biotinylation of histones increases in response to cell proliferation, whereas biotinidase activity was similar in nuclei from proliferating cells and quiescent controls (128). Finally, Gravel and coworkers (94) identified HCS as another enzyme that may catalyze biotinylation of histones.

Mechanisms mediating debiotinylation of histones are largely unknown. Recent studies suggested that biotinidase might catalyze both biotinylation and debiotinylation of histones (5). Variables such as the microenvironment in chromatin and posttranslational modifications and alternate splicing of biotinidase might determine whether biotinidase acts as biotinyl histone transferase or histone debiotinylase. This assumption is based on the following lines of reasoning. First, the availability of substrate might favor either biotinylation or debiotinylation of histones. For example, locally high concentrations of biocytin might increase the rate of histone biotinylation in confined regions of chromatin. Note that the pH is unlikely to affect the biotinylation equilibrium, given that the pH optimum is similar (pH 8) for both the biotinylating activity (67) and the debiotinylating activity of biotinidase (5). Second, proteins may interact with biotinidase at the chromatin level, favoring either biotinylation or debiotinylation of histones. Third, three alternatively spliced variants of biotinidase have been identified (127). Theoretically, these variants may have unique functions in histone metabolism. Fourth, some variants of biotinidase are modified posttranslationally by glycosylation (36, 127), potentially affecting enzymatic activity.

## Identification of Biotinylation Sites

Biotinylation sites in human histones were identified by using synthetic peptides (23, 24). Briefly, this approach is based on the following analytical sequence: (a) short peptides (<20 amino acids in length) are synthesized chemically; the amino acid sequences in these peptides are based on the sequence in a given region of a given histone; (b) peptides are incubated with biotinidase or HCS to conduct enzymatic biotinylation; (c) peptides are resolved by electrophoresis; and (d) biotin in peptides is probed using streptavidin peroxidase. Amino acid substitutions (e.g., lysine-to-alanine substitutions) and modifications (e.g., acetylation of lysines) in synthetic peptides can be used to corroborate identification of biotinylation sites and to investigate the cross-talk between biotinylation and other known modifications of histones, respectively (24). Using this approach, the following biotinylation sites have been identified in human histones: K9 and K13 in histone H2A (J. Zempeni, unpublished observation), K4, K9, and K18 in histone H3 (118), and K8 and K12 in histone H4 (24). Acetylation and phosphorylation

of lysine and serine residues, respectively, decrease biotinylation of adjacent lysine residues (24, 118). In contrast, dimethylation of arginine residues enhances biotinylation of adjacent lysine residues (118). This is consistent with studies suggesting that histones in livers from biotin-deficient rats showed unusual patterns of phosphorylation, methylation, and acetylation compared with biotin-sufficient controls (99).

## Biological Functions of Histone Biotinylation

Biotinylation of histones is a relatively new field of research; evidence of biological roles for biotinylation of histones is scarce. However, biotinylation of histones appears to participate in the following biological processes.

First, evidence showed that biotinylation of histones increases in response to cell proliferation in human PBMC (128). Biotinylation of histones increases early in the cell cycle (G1 phase) and remains increased during later phases (S, G2, and M phase) compared with quiescent controls; the increase is greater than fourfold. Fibroblasts from patients with HCS deficiency are severely deficient in histone biotinylation (94). It remains to be determined whether this is associated with decreased proliferation rates. Note that these studies were conducted before specific biotinylation sites in histones were identified and before biotinylation site-specific antibodies became available. Thus, these studies did not allow pinpointing changes in specific biotinylation sites; rather, the global biotinylation of histones was quantified by using streptavidin or radiolabeled biotin.

Second, studies in chicken erythrocytes have provided circumstantial evidence that biotinylated histones are enriched in transcriptionally silent chromatin (98).

Third, biotinylation of histones might play a role in the cellular response to DNA damage (76, 98). If formation of thymine dimers is caused by exposure of lymphoid cells to UV light, the global biotinylation of histones increases (98). If double-stranded DNA breaks are caused by exposure of lymphoid and choriocarcinoma cells to etoposide, biotinylation of K12 in histone H4 shows a rapid and transient decrease (76). This is consistent with a role for histone biotinylation in signaling DNA damage. These studies suggest that distinct kinds of DNA damage cause unique changes in histone biotinylation. Currently, it is unknown whether biotinylation of histones is a mechanism leading to DNA repair or apoptosis.

## Biotin Supply

Effects of biotin supply on biotinylation of histones have been investigated in various human-derived cell lines (39, 85, 119). In these studies, cell lines were cultured in media containing deficient, physiological, and pharmacological concentrations of biotin for several weeks. Biotin concentrations in culture media had only a moderate impact on biotinylation of histones; in contrast, biotinylation of carboxylases correlated strongly with biotin concentrations in culture media (39, 85, 119). The reader should note that even small changes in biotinylation of

histones might be physiologically meaningful, given that these changes might affect other modifications of histones such as acetylation and methylation.

## CONCLUSIONS AND OUTLOOK

In recent years, the groundwork has been laid to characterize roles for biotin in gene expression, cell signaling, and chromatin structure. Numerous clusters of biotin-dependent genes and signaling pathways have been identified. Biotin-dependent signaling pathways regulate the expression of genes that have important biological functions, e.g., in apoptosis and cell survival. Importantly, biotin-dependent cell signals converge at the level of chromatin: At least seven lysine residues in human histones are targets for biotinylation by biotinidase and HCS. Biotinylation of histones appears to be associated with cell proliferation, gene silencing, and the cellular response to DNA damage. Likely, more biotinylation sites in histones await identification. We anticipate that roles of biotin in cell signaling and chromatin structure will lead to the discovery of numerous novel roles for biotin in cell biology and human health, e.g., prevention of tumor initiation. Finally, one can expect to discover new biotinylated proteins in eukaryotic cells. Consistent with this assumption, we have identified novel biotinylation motifs in human proteins, including important signaling molecules (J. Zemleni, unpublished observation). Identification of new biotinylated proteins is likely to add substantially to the importance of biotin in cell biology.

## ACKNOWLEDGMENTS

This work was supported by NIH grants DK 60447 and DK 063945, and by NSF EPSCoR grant EPS-0346476. This chapter is a contribution of the University of Nebraska Agricultural Research Division, Lincoln, Nebraska.

**The *Annual Review of Nutrition* is online at <http://nutr.annualreviews.org>**

## LITERATURE CITED

1. Althaus F. 1992. Poly ADP-ribosylation: a histone shuttle mechanism in DNA excision repair. *J. Cell Sci.* 102:663–70
2. Armstrong SA, Barry DA, Leggett RW, Mueller CR. 1997. Casein kinase II-mediated phosphorylation of the C terminus of Sp1 decreases its DNA binding activity. *J. Biol. Chem.* 272:13489–95
3. Ausio J, van Holde KE. 1986. Histone hyperacetylation: its effect on nucleosome conformation and stability. *Biochemistry* 25:1421–28
4. Baldwin AS. 1996. The NF- $\kappa$ B and I $\kappa$ B proteins: new discoveries and insights. *Annu. Rev. Immunol.* 14:649–81
5. Ballard TD, Wolff J, Griffin JB, Stanley JS, van Calcar S, Zemleni J. 2002. Biotinidase catalyzes debiotinylation of histones. *Eur. J. Nutr.* 41:78–84
6. Barkett M, Gilmore TD. 1999. Control of apoptosis by Rel/NF- $\kappa$ B transcription factors. *Oncogene* 18:6910–24
7. Berg M, Dimroth P. 1998. The biotin protein MadF of the malonate decarboxylase

- from *Malonomonas rubra*. *Arch. Microbiol.* 170:464–68
8. Bergeron JJM, Brenner MB, Thomas DY, Williams DB. 1994. Calnexin: a membrane-bound chaperone of the endoplasmic reticulum. *Trends Biochem. Sci.* 19:124–28
  9. Bird AW, Yu DY, Pray-Grant MG, Qiu Q, Harmon KE, et al. 2002. Acetylation of histone H4 by Esa1 is required for DNA double-strand break repair. *Nature* 419:411–15
  10. Birnbaum MJ, van Wijnen AJ, Odgren PR, Last TJ, Suske G, et al. 1995. Sp1 trans-activation of cell cycle regulated promoters is selectively repressed by Sp3. *Biochemistry* 34:16503–8
  11. Black A, Black JD, Azizkhan-Clifford J. 2001. Sp1 and Krüppel-like factor family of transcription factors in cell growth regulation and cancer. *J. Cell. Physiol.* 188: 143–60
  12. Boas MA. 1927. The effect of desiccation upon the nutritive properties of egg-white. *Biochem. J.* 21:712–24
  13. Boland MP, Foster SJ, O'Neill LAJ. 1997. Daunorubicin activates NF $\kappa$ B and induces  $\kappa$ B-dependent gene expression in HL-60 promyelocytic and Jurkat T lymphoma cells. *J. Biol. Chem.* 272:12952–60
  14. Borboni P, Magnaterra R, Rabini RA, Staffolani R, Porzio O, et al. 1996. Effect of biotin on glucokinase activity, mRNA expression and insulin release in cultured beta-cells. *Acta Diabetol.* 33:154–58
  15. Bouliskas T. 1988. At least 60 ADP-ribosylated variant histones are present in nuclei from dimethylsulfate-treated and untreated cells. *EMBO J.* 7:57–67
  16. Bouliskas T, Bastin B, Bouliskas P, Dupuis G. 1990. Increase in histone poly (ADP-ribosylation) in mitogen-activated lymphoid cells. *Exp. Cell Res.* 187:77–84
  17. Bowers-Komro DM, McCormick DB. 1985. Biotin uptake by isolated rat liver hepatocytes. In *Biotin*, ed. K Dakshinamurti, HN Bhagavan, pp. 350–58. New York: NY Acad. Sci.
  18. Bowman BB, Selhub J, Rosenberg IH. 1986. Intestinal absorption of biotin in the rat. *J. Nutr.* 116:1266–71
  19. Brenner C. 2002. Catalysis in the nitri-lase superfamily. *Curr. Opin. Struct. Biol.* 12:775–82
  20. Brewer JW, Diehl JA. 2000. PERK mediates cell-cycle exit during the mammalian unfolded protein response. *Proc. Natl. Acad. Sci. USA* 97:12625–30
  21. Brownell JE, Zhou J, Ranalli T, Kobayashi R, Edmondson DG, et al. 1996. *Tetrahymena* histone acetyltransferase A: a homolog to yeast Gcn5p linking histone acetylation to gene activation. *Cell* 84:843–51
  22. Butz CE, McClelland GB, Brooks GA. 2004. MCT1 confirmed in rat striated muscle mitochondria. *J. Appl. Physiol.* 97: 1059–66
  23. Camporeale G, Chew YC, Kueh A, Sarath G, Zempleni J. 2005. Use of synthetic peptides for identifying biotinylation sites in human histones. In *Avidin-Biotin Technology in the Life Sciences*, ed. RJ McMahon. Totowa, NJ: Humana. In press
  24. Camporeale G, Shubert EE, Sarath G, Cerny R, Zempleni J. 2004. K8 and K12 are biotinylated in human histone H4. *Eur. J. Biochem.* 271:2257–63
  25. Caspersen C, Pedersen PS, Treiman M. 2000. The sarco/endoplasmic reticulum calcium-ATPase 2b is an endoplasmic reticulum stress-inducible protein. *J. Biol. Chem.* 275:22363–72
  26. Chambon P, Weill JD, Doly J, Strosser MT, Mandel P. 1966. On the formation of a novel adenylic compound by enzymatic extracts of liver nuclei. *Biochem. Biophys. Res. Commun.* 25:638–43
  27. Chang HI, Cohen ND. 1983. Regulation and intracellular localization of the biotin holocarboxylase synthetase of 3T3-L1 Cells. *Arch. Biochem. Biophys.* 225:237–47



28. Chatterjee NS, Kumar CK, Ortiz A, Rubin SA, Said HM. 1999. Molecular mechanism of the intestinal biotin transport process. *Am. J. Physiol.* 277:C605–13
29. Chatterjee NS, Rubin SA, Said HM. 2001. Molecular characterization of the 5' regulatory region of rat sodium-dependent multivitamin transporter gene. *Am. J. Physiol. Cell Physiol.* 280:C548–55
30. Chauhan J, Dakshinamurti K. 1991. Transcriptional regulation of the glucokinase gene by biotin in starved rats. *J. Biol. Chem.* 266:10035–8
31. Cheung P, Allis CD, Sassone-Corsi P. 2000. Signaling to chromatin through histone modifications. *Cell* 103:263–71
32. Deleted in proof
33. Chiba Y, Suzuki Y, Aoki Y, Ishida Y, Narisawa K. 1994. Purification and properties of bovine liver holocarboxylase synthetase. *Arch. Biochem. Biophys.* 313:8–14
34. Clayton AL, Mahadevan LC. 2003. MAP kinase-mediated phosphoacetylation of histone H3 and inducible gene regulation. *FEBS Lett.* 546:51–58
35. Cohen ND, Thomas M. 1982. Biotin transport into fully differentiated 3T3-L1 cells. *Biochem. Biophys. Res. Commun.* 108:1508–16
36. Cole H, Reynolds TR, Lockyer JM, Buck GA, Denson T, et al. 1994. Human serum biotinidase cDNA cloning, sequence, and characterization. *J. Biol. Chem.* 269:6566–70
37. Cole KH, Reynolds TR, Meyers GA, Pomponio RJ, Buck GA, Wolf B. 1998. Structure of the human biotinidase gene. *Mamm. Genome* 9:327–30
38. Collins JC, Paietta E, Green R, Morell AG, Stockert RJ. 1988. Biotin-dependent expression of the asialoglycoprotein receptor in HepG2. *J. Biol. Chem.* 263:11280–83
39. Crisp SERH, Camporeale G, White BR, Toombs CF, Griffin JB, et al. 2004. Biotin supply affects rates of cell proliferation, biotinylation of carboxylases and histones, and expression of the gene encoding the sodium-dependent multivitamin transporter in JAR choriocarcinoma cells. *Eur. J. Nutr.* 43:23–31
40. Cronan JE Jr. 1989. The *E. coli* bio operon: transcriptional repression by an essential protein modification enzyme. *Cell* 58:427–29
41. Dabbagh O, Brismar J, Gascon GG, Ozand PT. 1994. The clinical spectrum of biotin-treatable encephalopathies in Saudi Arabia. *Brain Dev.* 16(Suppl.):72–80
42. Daberkow RL, White BR, Cederberg RA, Griffin JB, Zemleni J. 2003. Monocarboxylate transporter 1 mediates biotin uptake in human peripheral blood mononuclear cells. *J. Nutr.* 133:2703–6
43. Dakshinamurti K. 2003. Regulation of gene expression by biotin, vitamin B6 and vitamin C. In *Molecular Nutrition*, eds. J Zemleni, H Daniel, pp. 151–65. Oxfordshire: CAB Int.
44. Dakshinamurti K, Chauhan J. 1994. Biotin-binding proteins. In *Vitamin Receptors: Vitamins as Ligands in Cell Communication*, ed. K Dakshinamurti, pp. 200–49. Cambridge, UK: Cambridge Univ. Press
45. Dakshinamurti K, Cheah-Tan C. 1968. Liver glucokinase of the biotin-deficient rat. *Can. J. Biochem.* 46:75–80
46. Dakshinamurti K, Litvak S. 1970. Biotin and protein synthesis in rat liver. *J. Biol. Chem.* 245:5600–5
47. Das KC, White CW. 1997. Activation of NF- $\kappa$ B by antineoplastic agents. *J. Biol. Chem.* 272:14914–20
48. Dey S, Subramanian VS, Chatterjee NS, Rubin SA, Said HM. 2002. Characterization of the 5' regulatory region of the human sodium-dependent multivitamin transporter, hSMVT. *Biochim. Biophys. Acta* 1574:187–92
49. Dimroth P. 1985. Biotin-dependent decarboxylases as energy transducing system. In *Biotin*, ed. K Dakshinamurti, HN Bhagavan, pp. 72–85. New York: NY Acad. Sci.

50. Dode L, Greef CD, Mountian I, Attard M, Town MM, et al. 1998. Structure of the human sarco-endoplasmic reticulum  $\text{Ca}^{2+}$ -ATPase 3 gene. *J. Biol. Chem.* 273:13982–94
51. Durkacz BW, Omidiji O, Gray DA, Shall S. 1980. (ADP-ribose)<sub>n</sub> participates in DNA excision repair. *Nature* 283:593–96
52. Edelstein LC, Lagos L, Simmons M, Tirumalai H, Gélinas C. 2003. NF- $\kappa$ B-dependent assembly of an enhanceosome-like complex on the promoter region of apoptosis inhibitor Bfl-1/A1. *Mol. Cell. Biol.* 23:2749–61
53. Fischle W, Wang Y, Allis CD. 2003. Histone and chromatin cross-talk. *Curr. Opin. Cell Biol.* 15:172–83
54. Freytag SO, Utter MF. 1983. Regulation of the synthesis and degradation of pyruvate carboxylase in 3T3-L1 cells. *J. Biol. Chem.* 258:6307–12
55. Ghayor G, Chadjichristos C, Herrouin J-F, Ala-Kokko L, Suske G, et al. 2001. Sp3 represses the Sp1-mediated transactivation of the human COL2A1 gene in primary and de-differentiated chondrocytes. *J. Biol. Chem.* 276:36881–95
56. Gorovsky MA. 1973. Macro- and micronuclei of *Tetrahymena pyriformis*: a model system for studying the structure of eukaryotic nuclei. *J. Protozool.* 20:19–25
57. Grafe F, Wohlrab W, Neubert RH, Brand-sch M. 2003. Transport of biotin in human keratinocytes. *J. Invest. Dermatol.* 120:428–33
58. Griffin JB, Rodriguez-Melendez R, Dode L, Wuytack F, Zempleni J. 2004. Biotin supplementation decreases the expression of the *SERCA3* gene in Jurkat cells, triggering unfolded protein response. Manuscript submitted
59. Griffin JB, Rodriguez-Melendez R, Zempleni J. 2003. The nuclear abundance of transcription factors Sp1 and Sp3 depends on biotin in Jurkat cells. *J. Nutr.* 133:3409–15
60. Griffin JB, Zempleni J. 2005. Biotin deficiency stimulates survival pathways in human lymphoma cells exposed to anti-neoplastic drugs. *J. Nutr. Biochem.* 16:96–103
61. Halestrap AP, Price NT. 1999. The proton-linked monocarboxylate transporter (MCT) family: structure, function and regulation. *Biochem. J.* 343:281–99
62. Hebbes TR, Thorne AW, Crane-Robinson C. 1988. A direct link between core histone acetylation and transcriptionally active chromatin. *EMBO J.* 7:1395–402
63. Hebert DN, Foellmer B, Helenius A. 1995. Glucose trimming and reglycosylation determine glycoprotein association with calnexin in the endoplasmic reticulum. *Cell* 81:425–33
64. Henderson BE, Ross RK, Pike MC. 1991. Toward the primary prevention of cancer. *Science* 254:1131–38
65. Hesketh R. 1997. *The Oncogene and Tumour Suppressor Gene FactsBook*. London: Academic. 549 pp.
66. Holmes-McNary MQ, Baldwin AS Jr, Zeisel SH. 2001. Opposing regulation of choline deficiency-induced apoptosis by p53 and nuclear factor  $\kappa$ B. *J. Biol. Chem.* 276:41197–204
67. Hymes J, Fleischhauer K, Wolf B. 1995. Biotinylation of histones by human serum biotinidase: assessment of biotinyl-transferase activity in sera from normal individuals and children with biotinidase deficiency. *Biochem. Mol. Med.* 56:76–83
68. Hymes J, Wolf B. 1999. Human biotinidase isn't just for recycling biotin. *J. Nutr.* 129:485S–89
69. Jenuwein T, Allis CD. 2001. Translating the histone code. *Science* 293:1074–80
70. Jeremias I, Kupatt C, Baumann B, Herr I, Wirth T, Debatin KM. 1998. Inhibition of nuclear factor  $\kappa$ B activation attenuates apoptosis resistance in lymphoid cells. *Blood* 91:4624–31
71. Jonas CR, Puckett AB, Jones DP, Griffith DP, Szeszycki EE, et al. 2000. Plasma antioxidant status after high-dose

- chemotherapy: a randomized trial of parenteral nutrition in bone marrow transplantation patients. *Am. J. Clin. Nutr.* 72: 181–89
72. Juarez-Salinas H, Sims JL, Jacobson MK. 1979. Poly(ADP-ribose) levels in carcinogen-treated cells. *Nature* 282:740–41
  73. Kim K-H, McCormick DB, Bier DM, Goodridge AG. 1997. Regulation of mammalian acetyl-coenzyme A carboxylase. *Annu. Rev. Nutr.* 17:77–99
  74. Knowles JR. 1989. The mechanism of biotin-dependent enzymes. *Annu. Rev. Biochem.* 58:195–221
  75. Kogl F, Tonnies B. 1932. Über das Bios-Problem. Darstellung von krystallisiertem Biotin aus Eigelb. *Z. Physiol. Chem.* 242: 43–73
  76. Kothapalli N, Zemleni J. 2004. Double strand breaks of DNA decrease biotinylation of lysine-12 in histone H4 in JAR cells. *FASEB J.* 18:A103–4
  77. Latchman DS. 1998. *Eukaryotic Transcription Factors*. San Diego, CA: Academic
  78. Laudet V, Gronemeyer H. 2002. *The Nuclear Receptor Facts Book*. San Diego, CA: Academic
  79. Lee DY, Hayes JJ, Pruss D, Wolffe AP. 1993. A positive role for histone acetylation in transcription factor access to nucleosomal DNA. *Cell* 72:73–84
  80. Leggett RW, Armstrong SA, Barry D, Mueller CR. 1995. Sp1 is phosphorylated and its DNA binding activity down-regulated upon terminal differentiation of the liver. *J. Biol. Chem.* 270:25879–84
  81. Li X, Stark GR. 2002. NF $\kappa$ B-dependent signaling pathways. *Exp. Hematol.* 30: 285–96
  82. Liehr JG, Ricci MJ. 1996. 4-Hydroxylation of estrogens as marker of human mammary tumors. *Proc. Natl. Acad. Sci. USA* 93:3294–96
  83. Lytton J, Westlin M, Burk SE, Shull GE, MacLennan DH. 1992. Functional comparisons between isoforms of the sarcolemmal or endoplasmic reticulum family of calcium pumps. *J. Biol. Chem.* 267: 14483–89
  84. Macher DRJ, Koch GLE. 1988. Identification of a set of calcium-binding proteins in reticuloplasm, the luminal content of the endoplasmic reticulum. *J. Cell Sci.* 91:61–70
  85. Manthey KC, Griffin JB, Zemleni J. 2002. Biotin supply affects expression of biotin transporters, biotinylation of carboxylases, and metabolism of interleukin-2 in Jurkat cells. *J. Nutr.* 132:887–92
  86. Maras B, Barra D, Dupre S, Pitari G. 1999. Is pantetheinase the actual identity of mouse and human vanin-1 proteins. *FEBS Lett.* 461:149–52
  87. Mardach R, Zemleni J, Wolf B, Cannon MJ, Jennings ML, et al. 2002. Biotin dependency due to a defect in biotin transport. *J. Clin. Invest.* 109:1617–23
  88. Mathis DJ, Oudet P, Waslyk B, Chambon P. 1978. Effect of histone acetylation on structure and in vitro transcription of chromatin. *Nucleic Acids Res.* 5:3523–47
  89. McCormick DB, Wright LD. 1971. The metabolism of biotin and analogues. In *Metabolism of Vitamins and Trace Elements*, ed. M Florkin, EH Stoltz, pp. 81–110. Amsterdam: Elsevier
  90. McMahon RJ. 2002. Biotin in metabolism and molecular biology. *Annu. Rev. Nutr.* 22:221–39
  91. Mock DM, Lankford GL, Cazin J Jr. 1993. Biotin and biotin analogs in human urine: biotin accounts for only half of the total. *J. Nutr.* 123:1844–51
  92. Mock DM, Lankford GL, Mock NI. 1995. Biotin accounts for only half of the total avidin-binding substances in human serum. *J. Nutr.* 125:941–46
  93. Mortensen ER, Marks PA, Shiotani A, Merchant JL. 1997. Epidermal growth factor and okadaic acid stimulate Sp1 proteolysis. *J. Biol. Chem.* 272:16540–47
  94. Narang MA, Dumas R, Ayer LM, Gravel RA. 2004. Reduced histone biotinylation

- in multiple carboxylase deficiency patients: a nuclear role for holocarboxylase synthetase. *Hum. Mol. Genet.* 13:15–23
95. Ozand PT, Gascon GG, Essa MA, Joshi S, Jishi EA, et al. 1998. Biotin-responsive basal ganglia disease: a novel entity. *Brain* 121(Pt. 7):1267–79
  96. Pacheco-Alvarez D, Solorzano-Vargas RS, Gravel RA, Cervantes-Roldan R, Velazquez A, Leon-Del-Rio A. 2004. Paradoxical regulation of biotin utilization in brain and liver and implications for inherited multiple carboxylase deficiencies. *J. Biol. Chem.* 279:52312–18
  97. Pahl HL. 1999. Signal transduction from the endoplasmic reticulum to the cell nucleus. *Physiol. Rev.* 79:683–700
  98. Peters DM, Griffin JB, Stanley JS, Beck MM, Zemleni J. 2002. Exposure to UV light causes increased biotinylation of histones in Jurkat cells. *Am. J. Physiol. Cell Physiol.* 283:C878–84
  99. Petrelli F, Coderoni S, Moretti P, Paparelli M. 1978. Effect of biotin on phosphorylation, acetylation, methylation of rat liver histones. *Mol. Biol. Rep.* 4:87–92
  100. Petrelli F, Moretti P, Paparelli M. 1979. Intracellular distribution of biotin-14C COOH in rat liver. *Mol. Biol. Rep.* 4:247–52
  101. Pham A-D, Sauer F. 2000. Ubiquitin-activating/conjugating activity of TAF<sub>II</sub>250, a mediator of activation of gene expression in *Drosophila*. *Science* 289:2357–60
  102. Pispas J. 1965. Animal biotinidase. *Ann. Med. Exp. Biol. Fenn.* 43:4–39
  103. Prasad PD, Ramamoorthy S, Leibach FH, Ganapathy V. 1997. Characterization of a sodium-dependent vitamin transporter mediating the uptake of pantothenate, biotin and lipoate in human placental choriocarcinoma cells. *Placenta* 18:527–33
  104. Prasad PD, Wang H, Huang W, Fei Y-J, Leibach FH, et al. 1999. Molecular and functional characterization of the intestinal Na<sup>+</sup>-dependent multivitamin transporter. *Arch. Biochem. Biophys.* 366:95–106
  105. Prasad PD, Wang H, Kekuda R, Fujita T, Fei Y-J, et al. 1998. Cloning and functional expression of a cDNA encoding a mammalian sodium-dependent vitamin transporter mediating the uptake of pantothenate, biotin, and lipoate. *J. Biol. Chem.* 273:7501–6
  106. Rao RV, Peel A, Logviniva A, Rio GD, Hermel E, et al. 2002. Coupling endoplasmic reticulum stress to the cell death program: role of the ER chaperone GRP78. *FEBS Lett.* 514:122–28
  107. Rodriguez-Melendez R, Griffin JB, Sarath G, Zemleni J. 2005. High-throughput immunoblotting identifies biotin-dependent signaling proteins in HepG2 hepatocarcinoma cells. Manuscript submitted
  108. Rodriguez-Melendez R, Griffin JB, Zemleni J. 2004. Biotin supplementation increases expression of the cytochrome P450 1B1 gene in Jurkat cells, increasing the occurrence of single-stranded DNA breaks. *J. Nutr.* 134:2222–28
  109. Rodriguez-Melendez R, Griffin JB, Zemleni J. 2005. The expression of genes encoding ribosomal subunits and eukaryotic translation initiation factor 5A depends on biotin and bisnorbiotin in HepG2 cells. Manuscript submitted
  110. Rodriguez-Melendez R, Lewis B, McMahon RJ, Zemleni J. 2003. Diaminobiotin and desthiobiotin have biotin-like activities in Jurkat cells. *J. Nutr.* 133:1259–64
  111. Rodriguez-Melendez R, Perez-Andrade ME, Diaz A, Deolarte A, Camacho-Arroyo I, et al. 1999. Differential effects of biotin deficiency and replenishment on rat liver pyruvate and propionyl-CoA carboxylases and on their mRNAs. *Mol. Genet. Metabol.* 66:16–23
  112. Rodriguez-Melendez R, Schwab LD, Zemleni J. 2004. Jurkat cells respond to biotin deficiency with increased nuclear translocation of NF- $\kappa$ B, mediating cell survival. *Int. J. Vitam. Nutr. Res.* 74:209–16

113. Rodriguez-Melendez R, Zempleni J. 2003. Regulation of gene expression by biotin. *J. Nutr. Biochem.* 14:680–90
114. Rohlf C, Ahmad S, Borellini F, Lei J, Glazer RI. 1997. Modulation of transcription factor Sp1 by cAMP-dependent protein kinase. *J. Biol. Chem.* 272:21137–41
115. Said HM. 1999. Cellular uptake of biotin: mechanisms and regulation. *J. Nutr.* 129:490S–93
116. Said HM. 2004. Recent advances in carrier-mediated intestinal absorption of water-soluble vitamins. *Annu. Rev. Physiol.* 66:419–46
117. Said HM, Redha R. 1987. A carrier-mediated system for transport of biotin in rat intestine in vitro. *Am. J. Physiol.* 252:G52–55
118. Sarath G, Kobza K, Rueckert B, Camporeale G, Zempleni J, Haas E. 2004. Biotinylation of human histone H3 and interactions with biotinidase. *FASEB J.* 18:A103
119. Scheerger SB, Zempleni J. 2003. Expression of oncogenes depends on biotin in human small cell lung cancer cells NCI-H69. *Int. J. Vitam. Nutr. Res.* 73:461–67
120. Shriver BJ, Roman-Shriver C, Allred JB. 1993. Depletion and repletion of biotinyl enzymes in liver of biotin-deficient rats: evidence of a biotin storage system. *J. Nutr.* 123:1140–49
121. Sidrauski C, Brickner JH, Walter P. 2002. The unfolded protein response. In *Protein Targeting, Transport & Translocation*, ed. RE Dalbey, GV Heijne, pp. 151–79. San Diego, CA: Academic
122. Singh IN, Dakshinamurti K. 1988. Stimulation of guanylate cyclase and RNA polymerase II activities in HeLa cells and fibroblasts by biotin. *Mol. Cell. Biochem.* 79:47–56
123. Slaviero KA, Read JA, Clarke SJ, Rivory LP. 2003. Baseline nutritional assessment in advanced cancer patients receiving palliative chemotherapy. *Nutr. Cancer* 46:148–57
124. Sloan GM, Maher M, Brennan MF. 1981. Nutritional effects of surgery, radiation therapy, and adjuvant chemotherapy for soft tissue sarcomas. *Am. J. Clin. Nutr.* 34:1094–102
125. Solorzano-Vargas RS, Pacheco-Alvarez D, Leon-Del-Rio A. 2002. Holocarboxylase synthetase is an obligate participant in biotin-mediated regulation of its own expression and of biotin-dependent carboxylases mRNA levels in human cells. *Proc. Natl. Acad. Sci. USA* 99:5325–30
126. Spence JT, Koudelka AP. 1984. Effects of biotin upon the intracellular level of cGMP and the activity of glucokinase in cultured rat hepatocytes. *J. Biol. Chem.* 259:6393–96
127. Stanley CM, Hymes J, Wolf B. 2004. Identification of alternatively spliced human biotinidase mRNAs and putative localization of endogenous biotinidase. *Mol. Genet. Metab.* 81:300–12
128. Stanley JS, Griffin JB, Zempleni J. 2001. Biotinylation of histones in human cells: effects of cell proliferation. *Eur. J. Biochem.* 268:5424–29
129. Strahl BD, Allis CD. 2000. The language of covalent histone modifications. *Nature* 403:41–45
130. Swango KL, Wolf B. 2001. Conservation of biotinidase in mammals and identification of the putative biotinidase gene in *Drosophila melanogaster*. *Mol. Genet. Metabol.* 74:492–99
131. Sweetman L. 1981. Two forms of biotin-responsive multiple carboxylase deficiency. *J. Inherit. Metab. Dis.* 4:53–54
132. Tang YM, Wo Y-YP, Stewart J, Hawkins AL, Griffin CA, et al. 1996. Isolation and characterization of the human cytochrome P450 *CYP1B1* gene. *J. Biol. Chem.* 271:28324–30
133. Taunton J, Hassig CA, Schreiber SL. 1996. A mammalian histone deacetylase related to a yeast transcriptional regulator Rpd3. *Science* 272:408–11
134. Tissot G, Pepin R, Job D, Douce R, Alban C. 1998. Purification and properties of the chloroplastic form of biotin holocarboxylase synthetase from *Arabidopsis thaliana*

- overexpressed in *Escherichia coli*. *Eur. J. Biochem.* 258:586–96
135. Tsuchiya Y, Nakajima M, Yokoi Y. 2003. Critical enhancer region to which AhR/ARNT and Sp1 bind in the human *CYP1B1* gene. *J. Biochem.* 133:583–92
  136. Turner BM. 2000. Histone acetylation and epigenetic code. *Bioessays* 22:836–45
  137. Wang C-Y, Guttridge DC, Mayo MW, Baldwin AS. 1999. NF- $\kappa$ B induces expression of the Bcl-2 homologue A1/Bfl-1 to preferentially suppress chemotherapy-induced apoptosis. *Mol. Cell. Biol.* 19:5923–29
  138. Wang C-Y, Mayo MW, Baldwin AS. 1996. TNF- and cancer therapy-induced apoptosis: potentiation by inhibition of NF- $\kappa$ B. *Science* 274:784–87
  139. Wiedmann S, Eudy JD, Zempleni J. 2003. Biotin supplementation causes increased expression of genes encoding interferon- $\gamma$ , interleukin-1 $\beta$ , and 3-methylcrotonyl-CoA carboxylase, and causes decreased expression of the gene encoding interleukin-4 in human peripheral blood mononuclear cells. *J. Nutr.* 133:716–19
  140. Wiedmann S, Rodriguez-Melendez R, Ortega-Cuellar D, Zempleni J. 2004. Clusters of biotin-responsive genes in human peripheral blood mononuclear cells. *J. Nutr. Biochem.* 15:433–39
  141. Wo Y-YP, Stewart J, Greenlee WF. 1997. Functional analysis of the promoter for the human *CYP1B1* gene. *J. Biol. Chem.* 272:26702–7
  142. Wolf B, Heard GS. 1991. Biotinidase deficiency. In *Advances in Pediatrics*, ed. L Barness, F Oski, pp. 1–21. Chicago: Medical Book Publ.
  143. Wolffe A. 1998. *Chromatin*. San Diego, CA: Academic
  144. Wood HG, Barden RE. 1977. Biotin enzymes. *Annu. Rev. Biochem.* 46:385–413
  145. Yoon YS, Kim JW, Kang KW, Kim YS, Choi KH, Joe CO. 1996. Poly(ADP-ribosyl)ation of histone H1 correlates with internucleosomal DNA fragmentation during apoptosis. *J. Biol. Chem.* 271:9129–34
  146. Yoshida H, Matsui T, Yamamoto A, Okada T, Mori K. 2001. XBP1 mRNA is induced by ATF6 and spliced by IRE1 in response to ER stress to produce a highly active transcription factor. *Cell* 107:881–91
  147. Zempleni J. 2001. Biotin. In *Present Knowledge in Nutrition*, ed. BA Bowman, RM Russell, pp. 241–52. Washington, DC: ILSI Press
  148. Zempleni J, Helm RM, Mock DM. 2001. In vivo biotin supplementation at a pharmacologic dose decreases proliferation rates of human peripheral blood mononuclear cells and cytokine release. *J. Nutr.* 131:1479–84
  149. Zempleni J, Mock DM. 1998. Uptake and metabolism of biotin by human peripheral blood mononuclear cells. *Am. J. Physiol. Cell Physiol.* 275:C382–88
  150. Zempleni J, Mock DM. 1999. Bioavailability of biotin given orally to humans in pharmacologic doses. *Am. J. Clin. Nutr.* 69:504–8
  151. Zempleni J, Mock DM. 1999. The efflux of biotin from human peripheral blood mononuclear cells. *J. Nutr. Biochem.* 10:105–9
  152. Zempleni J, Mock DM. 1999. Human peripheral blood mononuclear cells: Inhibition of biotin transport by reversible competition with pantothenic acid is quantitatively minor. *J. Nutr. Biochem.* 10:427–32

## CONTENTS

---

|   |     |
|---|-----|
| DIETARY FIBER: HOW DID WE GET WHERE WE ARE?, <i>Martin Eastwood and David Kritchevsky</i>   | 1   |
| DEFECTIVE GLUCOSE HOMEOSTASIS DURING INFECTION, <i>Owen P. McGuinness</i>   | 9   |
| HUMAN MILK GLYCANS PROTECT INFANTS AGAINST ENTERIC PATHOGENS, <i>David S. Newburg, Guillermo M. Ruiz-Palacios, and Ardythe L. Morrow</i>                        | 37  |
| NUTRITIONAL CONTROL OF GENE EXPRESSION: HOW MAMMALIAN CELLS RESPOND TO AMINO ACID LIMITATION, <i>M.S. Kilberg, Y.-X. Pan, H. Chen, and V. Leung-Pineda</i>      | 59  |
| MECHANISMS OF DIGESTION AND ABSORPTION OF DIETARY VITAMIN A, <i>Earl H. Harrison</i>  | 87  |
| REGULATION OF VITAMIN C TRANSPORT, <i>John X. Wilson</i>  | 105 |
| THE VITAMIN K-DEPENDENT CARBOXYLASE, <i>Kathleen L. Berkner</i>   | 127 |
| VITAMIN E, OXIDATIVE STRESS, AND INFLAMMATION, <i>U. Singh, S. Devaraj, and Ishwarlal Jialal</i>  | 151 |
| UPTAKE, LOCALIZATION, AND NONCARBOXYLASE ROLES OF BIOTIN, <i>Janos Zempleni</i>   | 175 |
| REGULATION OF PHOSPHORUS HOMEOSTASIS BY THE TYPE IIa Na/PHOSPHATE COTRANSPORTER, <i>Harriet S. Tenenhouse</i>   | 197 |
| SELENOPROTEIN P: AN EXTRACELLULAR PROTEIN WITH UNIQUE PHYSICAL CHARACTERISTICS AND A ROLE IN SELENIUM HOMEOSTASIS, <i>Raymond F. Burk and Kristina E. Hill</i>  | 215 |
| ENERGY INTAKE, MEAL FREQUENCY, AND HEALTH: A NEUROBIOLOGICAL PERSPECTIVE, <i>Mark P. Mattson</i>  | 237 |
| REDOX REGULATION BY INTRINSIC SPECIES AND EXTRINSIC NUTRIENTS IN NORMAL AND CANCER CELLS, <i>Archana Jaiswal McEligot, Sun Yang, and Frank L. Meyskens, Jr.</i> | 261 |
| REGULATION OF GENE TRANSCRIPTION BY BOTANICALS: NOVEL REGULATORY MECHANISMS, <i>Neil F. Shay and William J. Banz</i>  | 297 |

|   |     |
|---|-----|
| POLYUNSATURATED FATTY ACID REGULATION OF GENES OF LIPID METABOLISM, <i>Harini Sampath and James M. Ntambi</i>   | 317 |
| SINGLE NUCLEOTIDE POLYMORPHISMS THAT INFLUENCE LIPID METABOLISM: INTERACTION WITH DIETARY FACTORS, <i>Dolores Corella and Jose M. Ordovas</i>   | 341 |
| THE INSULIN RESISTANCE SYNDROME: DEFINITION AND DIETARY APPROACHES TO TREATMENT, <i>Gerald M. Reaven</i>  | 391 |
| DEVELOPMENTAL DETERMINANTS OF BLOOD PRESSURE IN ADULTS, <i>Linda Adair and Darren Dahly</i>   | 407 |
| PEDIATRIC OBESITY AND INSULIN RESISTANCE: CHRONIC DISEASE RISK AND IMPLICATIONS FOR TREATMENT AND PREVENTION BEYOND BODY WEIGHT MODIFICATION, <i>M.L. Cruz, G.Q. Shaibi, M.J. Weigensberg, D. Spruijt-Metz, G.D.C. Ball, and M.I. Goran</i> | 435 |
| ANNUAL LIPID CYCLES IN HIBERNATORS: INTEGRATION OF PHYSIOLOGY AND BEHAVIOR, <i>John Dark</i>  | 469 |
| <i>DROSOPHILA</i> NUTRIGENOMICS CAN PROVIDE CLUES TO HUMAN GENE–NUTRIENT INTERACTIONS, <i>Douglas M. Ruden, Maria De Luca, Mark D. Garfinkel, Kerry L. Bynum, and Xiangyi Lu</i>  | 499 |
| THE COW AS A MODEL TO STUDY FOOD INTAKE REGULATION, <i>Michael S. Allen, Barry J. Bradford, and Kevin J. Harvatine</i>  | 523 |
| THE ROLE OF ESSENTIAL FATTY ACIDS IN DEVELOPMENT, <i>William C. Heird and Alexandre Lapillonne</i>  | 549 |
| INDEXES   |     |
| Subject Index   | 573 |
| Cumulative Index of Contributing Authors, Volumes 21–25   | 605 |
| Cumulative Index of Chapter Titles, Volumes 21–25   | 608 |

## ERRATA

An online log of corrections to *Annual Review of Nutrition* chapters may be found at <http://nutr.annualreviews.org/>